<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Eighteen patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> received <z:chebi fb="0" ids="6067">13-cis-retinoic acid</z:chebi> (1.0-mg/kg/day starting dose with 0.5-mg/kg increment escalations) in a phase I-II trial </plain></SENT>
<SENT sid="1" pm="."><plain>Two partial responses involving the erythroid series were observed in four patients with primary <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with ring sideroblasts </plain></SENT>
<SENT sid="2" pm="."><plain>One of two patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> also achieved a partial response </plain></SENT>
<SENT sid="3" pm="."><plain>No other responses were found in the remaining patients, which included eight with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts </plain></SENT>
<SENT sid="4" pm="."><plain>In six patients drug toxicity necessitated termination of the trial </plain></SENT>
<SENT sid="5" pm="."><plain>Four patients had unexpected drug-induced <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>; three of these had <z:hpo ids='HP_0001873'>low platelet counts</z:hpo> before treatment </plain></SENT>
<SENT sid="6" pm="."><plain>Two of the six patients had other toxic effects </plain></SENT>
<SENT sid="7" pm="."><plain>Further studies are warranted to evaluate the effectiveness of <z:chebi fb="0" ids="6067">13-cis-retinoic acid</z:chebi> in patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with ring sideroblasts and <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>At moderate doses significant toxic effects, including <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, are not uncommon </plain></SENT>
</text></document>